UK-based Microvisk Technologies has announced its plans to launch its CoagMax and CoagLite blood-clot monitoring devices in the U.S. market in mid-2012. Before that happens, however, the company is planning on conducting clinical trials involving 250 patients. The trials will take place at three major cardiac centers in Florida in October.
Designed for use for patients taking anti-coagulant drugs such as warfarin (Coumadin), the devices can help monitor treatment and determine the optimal drug dose. The CoagMax system is designed for point-of-care use while the CoagLite is designated for use in the home. Both systems use micro-electro-mechanical sensors (MEMS) on a disposable strip incorporating a cantilever to measure blood viscosity. By contrast, other coagulation monitoring devices on the market generally use optical analysis or a chemical reaction to do so.
In the United Kingdom and in Germany, multi-center clinical trials involving the CoagMax and CoagLite systems are already in progress. The products are ready to launch in Europe in early 2012.
Link: Microvisk Technologies